“Sell Affimed” is Today’s Cool Trade
Research - AFMD is up nearly 200% in less than two months. Taking profit is already a crowding trade on Monday, but we want to be doing … Continue Reading
Premium: Read NowResearch
Cempra’s SOLITAIRE-IV Results are Just Months Away
Research - Cempra (CEMP) announced on Tuesday that enrollment in the phase III SOLITAIRE-IV trial is complete, and the company expects data from the study in the … Continue Reading
Read Now
Marinus Pharmaceuticals Clears Up 2015 Events – Sort Of
Research - PCDH19 female epilepsy is associated with low levels of allopregnanolone in the blood, a neurosteroid, hormone metabolite, and a positive allosteric modulator of the GABAa receptor.
Premium: Read Now
Buying When There’s Blood in the Streets
Research - Investors who were involved for the now-failed Alzheimer’s program are vacating the stock. That’s an opportunity for new investors, like us, looking further down the road to what could be a compelling and novel diabetes treatment.
Premium: Read Now
Biotech Finally Breaks Through the Wall
Research - Biotech is finally breaking out to new all-time highs, and you’ll be hard-pressed to find much red on your watch-list. We wrote about the current … Continue Reading
Read Now
Synergy Exceeds Expectations in Latest Study
Research - Synergy Pharmaceuticals (SGYP) reported positive data from the first of two phase 3 trials for its constipation drug plecanatide on Wednesday.
Read Now
Takeaways From bluebird’s Latest Presentation
Research - This weekend, bluebird bio (BLUE) and investigators presented much-awaited data for the first Sickle Cell Disease (SCD) patient treated with LentiGlobin (BB305) in the HBG-205 … Continue Reading
Read Now